Infinity Pharmaceuticals Inc. Reports New Preclinical Data for Saridegib at American Association for Cancer Research Supporting Development in Residual Disease Settings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today presented new preclinical data for saridegib (IPI-926), its novel oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway. Data presented showed the anti-tumor activity of saridegib in models of residual disease, in which malignant cells remain present after primary treatment. Importantly, these data show that the ability of saridegib to delay tumor recurrence is time dependent and provide rationale for the development of saridegib in residual disease settings, such as ovarian cancer and small cell lung cancer. These data were presented during a mini symposium session at the American Association for Cancer Research (AACR) 103rd Annual Meeting in Chicago, Illinois (Abstract #979).

Back to news